MDACC Study No:2012-1159 ( NCT No: NCT01711528)
Title:Phase 1 Clinical Trial of A Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Principal Investigator:Sheeba K. Thomas
Treatment Agent:Bortezomib; Dexamethasone; Dinaciclib
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of dinaciclib that can be given in combination with bortezomib and

Dinaciclib is designed to stop cancer cells from dividing into new cancer
cells. It may also make cancer cells more sensitive to chemotherapy drugs.

Bortezomib is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Bortezomib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults